GlucoTrack Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Mean Absolute Relative Difference (MARD) Quarterly7.7Target: < 10.0%
Data Capture Rate Quarterly9,900.0%Target: 99.0%
Cash and Cash Equivalents Quarterly3.9MTarget: Sufficient to fund clinical trials
Watch Items
- FDA Investigational Device Exemption (IDE) ApprovalTrigger: Approval of IDE submission for U.S. human clinical trialsAction: Initiate U.S. human clinical trials in the second half of 2026
- Nasdaq Listing ComplianceTrigger: Minimum bid price below $1.00 and stockholders' equity below $2,500,000Action: Execute reverse stock split (up to 1-for-30 authorized) and raise equity capital
- Cash Runway and Capital RaisingTrigger: Cash depletion expected in early Q3 2026Action: Utilize Sixth Borough Capital Fund equity line or execute warrant inducement/repricing
Research as of 20 Jun 2026